Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.34 |
| ▸ | CHUK | O15111 | 6/20 | 0.34 |
| ▸ | YTHDC1 | Q96MU7 | 4/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | ITK | Q08881 | 1/20 | 0.30 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206535 | 1.00 | IKBKB (0.34) | IKBKBCHUKYTHDC1EGLN1PDE4A | |
| SCHEMBL29173707 | 0.90 | IKBKB (0.33) | IKBKBCHUKYTHDC1PDE4APDE4B | |
| SCHEMBL30802785 | 0.90 | IKBKB (0.33) | IKBKBCHUKYTHDC1PDE4APDE4B | |
| Formic Acid SCHEMBL30206200 | 0.86 | IKBKB (0.31) | IKBKBCHUKYTHDC1CCNCCDK8 | |
| Formic Acid SCHEMBL30206363 | 0.86 | IKBKB (0.31) | IKBKBCHUKYTHDC1CCNCCDK8 | |
| Formic Acid SCHEMBL30205937 | 0.86 | IKBKB (0.31) | IKBKBCHUKYTHDC1CCNCCDK8 | |
| SCHEMBL30206235 | 0.80 | CCNC (0.32) | EGLN1CCNCCDK8 | |
| SCHEMBL30206286 | 0.79 | EIF4EBP1 (0.37) | IKBKBCHUKYTHDC1EGLN1PDE4A | |
| SCHEMBL29173737 | 0.79 | IKBKB (0.32) | IKBKBCHUKYTHDC1PDE4APDE4B | |
| SCHEMBL30206345 | 0.78 | EGLN1 (0.34) | EGLN1CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | IKBKB 505/4885CHUK 103/4885YTHDC1 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.